Krystal Biotech (KRYS) is back in focus after the United Kingdom granted marketing authorization for VYJUVEK, the first genetic medicine approved there for dystrophic epidermolysis bullosa, with orphan status and potential 12-year exclusivity.

At a latest share price of US$299.45, Krystal Biotech has pulled back over the past week but still shows a 30 day share price return of 9.88% and a 1 year total shareholder return of 139.46% relating to VYJUVEK approvals in multiple regions.

If this kind of move in a single biotech stock has your attention, it could be a moment to see what else is setting up across 34 healthcare AI stocks.

With Krystal Biotech now valued at roughly US$8.8b and VYJUVEK authorized across major regions, the key question is whether the recent success still leaves upside on the table, or if markets are already pricing in future growth.

Most Popular Narrative: 4.9% Undervalued

Compared with the last close of US$299.45, the most followed narrative pegs Krystal Biotech's fair value at US$315, suggesting a modest gap the market has yet to close.

The analysts have a consensus price target of $315.0 for Krystal Biotech based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $380.0, and the most bearish reporting a price target of just $241.0.

Curious what kind of revenue ramp, margin profile and future earnings multiple are reflected in that fair value number? The full narrative walks through the forecasts, the spread between bullish and cautious views, and how all of that contributes to the US$315 figure.

Result: Fair Value of $315 (UNDERVALUED)

However, this hinges on VYJUVEK avoiding rollout setbacks, and on multiple registrational and early stage programs progressing without major clinical or reimbursement surprises.

Another Angle On Valuation

Analysts see Krystal Biotech as about 4.9% undervalued using their fair value of US$315, but the current P/E of 39.2x tells a different story when set against the Biotechs industry at 16.2x, peers at 12.3x and a fair ratio of 28.4x. This raises the question of whether the premium signals extra risk or extra opportunity for you.

Next Steps

If the mix of optimism and caution in this article resonates, consider reviewing the numbers and risks for yourself, starting with 3 key rewards.

Looking for more investment ideas?

If Krystal Biotech has sharpened your focus, do not stop here. The market is full of other stocks with different return and risk profiles worth sizing up.

• Spot potential value opportunities early by scanning companies that appear mispriced relative to their fundamentals using the 49 high quality undervalued stocks.
• Prioritize stability by reviewing stocks that screen well on balance sheet strength and core metrics with the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for underfollowed opportunities by checking a screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.